0.2.1 What Makes Nicotine Addictive

Differentiate abuse liability by nicotine delivery kinetics

Abuse liability correlates strongly with the rate of drug delivery to the CNS. Inhaled nicotine via combustible cigarettes achieves peak arterial concentrations within 10-20 seconds, creating a sharp bolus to the mesolimbic system.¹ E-cigarettes approximate this kinetics depending on device generation. NRT products (patch, gum, lozenge) have deliberately slower absorption curves to provide therapeutic nicotine with reduced reinforcement potential.²

Explain mesolimbic pathway activation and receptor upregulation to frame pharmacotherapy

Nicotine activates alpha-4-beta-2 nicotinic acetylcholine receptors (nAChRs) on ventral tegmental area (VTA) neurons, stimulating dopamine release in the nucleus accumbens.¹ Chronic exposure leads to receptor desensitisation followed by compensatory upregulation - increasing nAChR density by 25-50%.² This upregulation underlies tolerance and the intensity of withdrawal. Varenicline's efficacy rests on partial agonism at these same receptors, providing low-level dopaminergic stimulation while blocking nicotine's reinforcing bolus.

Time pharmacotherapy to cover the acute withdrawal window

Nicotine withdrawal symptoms (DSM-5 criteria: irritability, anxiety, difficulty concentrating, increased appetite, restlessness, depressed mood, insomnia) typically peak at 48-72 hours post-cessation and largely resolve within 2-4 weeks.¹ NRT or varenicline should ideally be initiated before or on the quit date to blunt this peak. Bupropion requires a 1-2 week lead-in period. Monitoring should be more frequent during the first two weeks, tapering as acute symptoms resolve.

Use diagnostic language deliberately to reduce patient self-stigma

Framing nicotine dependence as a chronic medical condition (ICD-11: 6C4A, DSM-5: 305.1/F17.200) rather than a behavioural choice has measurable effects on patient engagement and treatment-seeking.¹ Studies on addiction stigma show that biogenetic framing increases willingness to pursue pharmacotherapy and reduces internalised shame.² Clinicians should explicitly name nicotine dependence as a medical diagnosis during consultations, particularly with patients who express guilt or self-blame about continued use.